William Blair Reaffirms “Market Perform” Rating for Catalent (NYSE:CTLT)

Catalent (NYSE:CTLT)‘s stock had its “market perform” rating reissued by research analysts at William Blair in a research report issued on Tuesday, Benzinga reports.

A number of other equities research analysts have also issued reports on the company. Barclays increased their target price on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Finally, StockNews.com initiated coverage on Catalent in a research note on Monday. They issued a “sell” rating for the company. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $58.64.

Catalent Price Performance

CTLT stock opened at $60.72 on Tuesday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51. Catalent has a 1 year low of $31.80 and a 1 year high of $61.20. The firm has a market cap of $10.99 billion, a P/E ratio of -9.95, a price-to-earnings-growth ratio of 2.52 and a beta of 1.16. The stock has a 50-day simple moving average of $58.72 and a 200-day simple moving average of $57.04.

Insider Activity at Catalent

In other Catalent news, CFO Matti Masanovich sold 2,993 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the transaction, the chief financial officer now owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Catalent news, insider Ricky Hopson sold 662 shares of the stock in a transaction that occurred on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Matti Masanovich sold 2,993 shares of the stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total value of $169,822.82. Following the transaction, the chief financial officer now directly owns 33,871 shares in the company, valued at approximately $1,921,840.54. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,409 shares of company stock valued at $782,923. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Nisa Investment Advisors LLC lifted its holdings in shares of Catalent by 1.7% in the 2nd quarter. Nisa Investment Advisors LLC now owns 11,013 shares of the company’s stock worth $619,000 after purchasing an additional 185 shares during the last quarter. Lindbrook Capital LLC lifted its holdings in shares of Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after purchasing an additional 208 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after purchasing an additional 212 shares during the last quarter. Czech National Bank lifted its holdings in shares of Catalent by 0.7% in the 1st quarter. Czech National Bank now owns 31,801 shares of the company’s stock worth $1,795,000 after purchasing an additional 228 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in shares of Catalent by 1.4% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 19,238 shares of the company’s stock worth $1,082,000 after purchasing an additional 257 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.